3692 — Hansoh Pharmaceutical Balance Sheet
0.000.00%
- HK$221.01bn
- HK$191.55bn
- CNY12.26bn
- 99
- 12
- 95
- 82
Annual balance sheet for Hansoh Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 13,718 | 18,933 | 21,623 | 24,857 | 23,386 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3,210 | 3,782 | 3,674 | 3,321 | 3,265 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17,286 | 23,179 | 25,832 | 28,883 | 27,442 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,468 | 3,569 | 3,483 | 3,294 | 3,268 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 20,792 | 27,160 | 30,002 | 33,039 | 31,658 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,690 | 3,024 | 2,620 | 6,863 | 2,695 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2,916 | 7,131 | 7,355 | 7,244 | 2,978 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 17,876 | 20,029 | 22,647 | 25,795 | 28,680 |
| Total Liabilities & Shareholders' Equity | 20,792 | 27,160 | 30,002 | 33,039 | 31,658 |
| Total Common Shares Outstanding |